MARKET

ALPN

ALPN

Alpine Immune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.33
+0.13
+1.16%
Closed 16:00 04/09 EDT
OPEN
11.17
PREV CLOSE
11.20
HIGH
11.54
LOW
10.79
VOLUME
122.19K
TURNOVER
--
52 WEEK HIGH
16.37
52 WEEK LOW
2.580
MARKET CAP
270.58M
P/E (TTM)
-8.0252
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight
Biotech stocks ended the holiday-shortened week ended April 1 in the green, catalyzed by the broader market rebound and a slew of company-specific news flow. Buoyed by hopes of a U.S.
Benzinga · 04/03 13:11
Alpine Immune Sciences (NASDAQ:ALPN) Is Using Debt Safely
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Simply Wall St. · 03/21 08:30
The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 18)
Benzinga · 03/19 11:46
Alpine Immune Sciences (ALPN) Receives a Rating Update from a Top Analyst
SmarterAnalyst · 03/19 10:25
Oppenheimer Assigns a Buy Rating on Alpine Immune Sciences (ALPN)
In a report released today, Mark Breidenbach from Oppenheimer assigned a Buy rating to Alpine Immune Sciences (ALPN), with a price target of $19.00. The
SmarterAnalyst · 03/19 04:35
8-K: ALPINE IMMUNE SCIENCES, INC.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/19 04:17
DJ Alpine Immune Sciences, Inc. CEO Mitchell Gold on Q4 2020 Results -- Earnings Call Transcript >ALPN
Dow Jones · 03/19 02:33
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com · 03/19 02:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALPN. Analyze the recent business situations of Alpine Immune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALPN stock price target is 21.40 with a high estimate of 27.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 57
Institutional Holdings: 14.56M
% Owned: 60.96%
Shares Outstanding: 23.88M
TypeInstitutionsShares
Increased
13
1.27M
New
11
595.70K
Decreased
8
1.29M
Sold Out
2
4.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.53%
Pharmaceuticals & Medical Research
+0.26%
Key Executives
Chairman/Chief Executive Officer/Chief Compliance Officer/Executive Director
Mitchell Gold
President
Stanford Peng
Chief Financial Officer/Senior Vice President/Secretary
Paul Rickey
Senior Vice President
Pamela Holland
Chief Technology Officer
Wayne Gombotz
Other
Remy Durand
Independent Director
Min Cui
Director
Natasha Hernday
Director
Jay Venkatesan
Independent Director
Robert Conway
Independent Director
Xiangmin Cui
Independent Director
Christopher Peetz
Independent Director
Peter Thompson
Independent Director
James Topper
No Data
  • All
  • Financials
  • Insiders
More
About ALPN
Alpine Immune Sciences, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The Company's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. Its product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.

Webull offers kinds of Alpine Immune Sciences Inc stock information, including NASDAQ:ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.